EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration

Simone Adorinni iD, Ilenia Grieco iD, Stefano Morasso, Michelle Fornasier iD, Gianluca Novello iD, Veronica Salmaso, Loreto Martínez-González, Eleonora Cescon, Davide Bassani, Giovanni Adriano Bassan iD, Teresa Gianferrara, Filippo Prencipe und 7 weitere

ChemMedChem · 28.10.2026 · 21 (20)

DOI: 10.1002/cmdc.70539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 22.10.2026. Verfasst von Simone Adorinni und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Riluzole, Casein Kinase Idelta, Protein Kinase Inhibitors. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Riluzole‐derived benzo[d]thiazoles were investigated as metabolite‐inspired CK1 δ inhibitors, a kinase involved in TDP‐43 phosphorylation and therefore relevant to amyotrophic lateral sclerosis (ALS). Starting from the known CK1 δ activity of riluzole, we examined whether its major hydroxylamine metabolite could preserve target recognition and provide a rational entry point for scaffold optimisation. The metabolite retained CK1 δ inhibition, but its limited chemical stability and toxicity in neuronal cells identified the hydroxylamine group as a critical liability. Replacement of this functionality with a hydrazine converted the fragile metabolite‐derived structure into a more potent and tractable CK1 δ inhibitor series. Structure–activity relationship studies revealed that the hydrazine moiety accommodates broader substitution than the hydroxylamine counterparts, with branched alkyl and benzyl groups giving the most balanced profiles. Docking and molecular dynamics suggested that the improvement could be attributed to an additional hydrogen‐bond with Gly86 in the hinge region. The best derivative combined submicromolar CK1 δ inhibition with passive blood–brain barrier permeability, short‐term cellular tolerance, ATP competitive inhibition, direct target engagement, and preliminary selectivity over GSK3β. Although this compound did not result neuroprotective in an oxidative stress model, it paves the way for a focused benzo[d]thiazole platform for probing CK1 δ biology in ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisRiluzoleCasein Kinase IdeltaProtein Kinase InhibitorsBenzothiazolesNeuroprotective AgentsHumansStructure-Activity RelationshipAnimalsMolecular Docking SimulationMolecular Structure

Stichwörter der Autor:innen

Casein kinase 1δbenzo[d]thiazoleslateral sclerosismetabolism‐based drug designriluzole

Substanzen

RiluzoleCasein Kinase IdeltaProtein Kinase InhibitorsBenzothiazolesNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
  • Protein Targets for Drug Discovery Lab, Structural Biology, Elettra Sincrotrone Trieste S.C.p.A, Basovizza, Italy.
  • Molecular Modelling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padova, Italy.
  • Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

ORCID-Profile: Simone Adorinni, Ilenia Grieco, Michelle Fornasier, Gianluca Novello, Giovanni Adriano Bassan, Tatiana Da Ros, Paola Storici, Ana Martinez, Giampiero Spalluto, Stefano Moro, Stephanie Federico

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Adorinni, S., Grieco, I., Morasso, S., Fornasier, M., Novello, G., Salmaso, V., Martínez-González, L., Cescon, E., Bassani, D., Bassan, G. A., Gianferrara, T., Prencipe, F., Kost, V., Da Ros, T., Storici, P., Martinez, A., Spalluto, G., Moro, S., & Federico, S. (2026). Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70539

Vancouver

Adorinni S, Grieco I, Morasso S, Fornasier M, Novello G, Salmaso V, et al. Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70539

BibTeX
@article{Adorinni2026,
  author = {Adorinni, Simone and Grieco, Ilenia and Morasso, Stefano and Fornasier, Michelle and Novello, Gianluca and Salmaso, Veronica and Martínez-González, Loreto and Cescon, Eleonora and Bassani, Davide and Bassan, Giovanni Adriano and Gianferrara, Teresa and Prencipe, Filippo and Kost, Veronika and Da Ros, Tatiana and Storici, Paola and Martinez, Ana and Spalluto, Giampiero and Moro, Stefano and Federico, Stephanie},
  title = {Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {20},
  doi = {10.1002/cmdc.70539}
}
Kostenlos starten →